A New Method for Evaluation of Urinary Autocrine Motility Factor and Tumor Cell Collagenase Stimulating Factor as Markers for Urinary Tract Cancers

Over the past several years, many tumor markers, including cell surface antigens, T-antigen, ras p55, and ras p52 proteins, have been studied as potential tumor markers of bladder cancer. The lack of specificity and inconsistency of these markers led us to develop a new method for studying the urina...

Full description

Saved in:
Bibliographic Details
Published in:Journal of occupational and environmental medicine 1990-09, Vol.32 (9), p.846-853
Main Authors: Guirguis, Raouf, Javadpour, Nasser, Sharareh, Sheri, Biswas, Chitra, El-Amin, Wael, Mansur, Izzuddin, Kim, Jeong Soon
Format: Article
Language:English
Subjects:
Antigens, CD
Antigens, Neoplasm
Basigin
Biological and medical sciences
Biomarkers, Tumor - urine
Detection Techniques
Enzyme-Linked Immunosorbent Assay
Glucose-6-Phosphate Isomerase
Humans
Medical sciences
Membrane Glycoproteins - urine
Neoplasm Proteins - urine
Nephrology. Urinary tract diseases
Regression Analysis
Single-Blind Method
Tumors of the urinary system
Urinary tract. Prostate gland
Urologic Neoplasms - diagnosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past several years, many tumor markers, including cell surface antigens, T-antigen, ras p55, and ras p52 proteins, have been studied as potential tumor markers of bladder cancer. The lack of specificity and inconsistency of these markers led us to develop a new method for studying the urinary excretion of autocrine motility factor (uAMF) and tumor cell collagenase stimulating factor (TCSF) in 24-hour and first morning voided specimens. AMF is a glycoprotein secreted by the malignant cells and is responsible for cell locomotion, a key event in invasion and metastases of the malignant cells. TCSF is a membrane bound glycoprotein of tumor cells that stimulates fibroblast collagenase production. We have utilized an enzyme-linked immunoabsorption assay to detect the levels of uAMF and TCSF in urine samples collected from normal volunteers, patients with benign diseases, and patients with bladder cancer. Our data indicate that urinary concentrations of uAMF and TCSF are elevated in patients with bladder cancer. Furthermore, the levels of uAMF and TCSF are more elevated in invasive tumors as compared with benign counterparts. We have localized uAMF and TCSF in bladder cancer cells, utilizing immunohistologic techniques.
ISSN:0096-1736
1076-2752
2332-3795
DOI:10.1097/00043764-199009000-00017